UK and US agree zero-tariff deal on pharmaceuticals
go - Officials say the U.K. has sealed a deal securing a 0% tariff rate for all U.K. medicines exported to the U.S. for at least 3 years, in return for the U.K. spending more on new medicines
AI Summary: In a twist worthy of a Hollywood trade drama, officials announced that the UK and US have struck a deal to impose zero tariffs on UK‐made medicines destined for the US. As part of the arrangement, the UK must shell out considerably more for drug pricing—a move set to avoid tariffs that could soar as high as 100%—with the agreement effective for at least three years.
Novo Nordisk rolls out lower prices for Ozempic and Wegovy
medicalxpress - People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.
AI Summary: In a bid to ease the financial burden on self‐pay patients, Novo Nordisk has unveiled deep price cuts for its flagship GLP-1 drugs, Ozempic and Wegovy. The new pricing strategy comes amid intensifying market pressures and aims to broaden access to these critical therapies for weight management and type 2 diabetes.
CMS unveils new Medicaid drug payment model
Max Bayer / endpoints - CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump's "most favored nation" push that the pharma industry has been closely ...
AI Summary: The Centers for Medicare and Medicaid Services has introduced a novel Medicaid drug payment model that employs a most-favored nation pricing strategy, aiming to rein in healthcare spending. This bold move signals a shift toward competitive pricing that, while promising cost efficiencies, also raises eyebrows over its unorthodox approach.
What Trump’s New Drug Pricing Deal Means for People With Obesity
Rebecca Robbins, Dani Blum and Margot Sanger-Katz / nytimes - The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
AI Summary: In a bold move to tackle the obesity crisis, the Trump administration has brokered agreements with industry giants such as Eli Lilly and Novo Nordisk to slash weight-loss drug prices. The deals, promising reductions as steep as $149 a month, have sparked both applause and debate over the future of drug pricing in America.